Euroscreen Appoints Geert Cauwenbergh and Yves Ribeill as Directors

EUROSCREEN S.A. announced today that it has appointed Dr. Geert Cauwenbergh, former CEO of Barrier Therapeutics Inc. and Dr. Yves Ribeill, CEO of Scynexis, Inc., to its board of directors, adding significant, further depth and expertise to EUROSCREEN's board.

Brussels, Belgium (PRWEB) July 14, 2008 -- EUROSCREEN S.A. announced today that it has appointed Dr. Geert Cauwenbergh, former CEO of Barrier Therapeutics Inc. and Dr. Yves Ribeill, CEO of Scynexis, Inc., to its board of directors, adding significant, further depth and expertise to EUROSCREEN's board.

"The extensive track records of Geert and Yves will be valuable additions for EUROSCREEN to advance its drug development pipeline towards the clinic" stated Dr. Jean Combalbert, EUROSCREEN's CEO. "We believe that their complementary abilities and knowledge in transitioning an early stage biotechnology company into a world leader will play a significant role as Euroscreen moves forward."

Geert Cauwenbergh, PhD, recently founded Phases123 LLC. Before, Geert founded Barrier Therapeutics in September 2001, and served as CEO up to April 2008. He took the company public (symbol: BTRX on Nasdaq) in April of 2004. Prior, Geert held various positions during the 21 years of his international career with Janssen Pharmaceutica and Johnson & Johnson. Geert is also a Director of Ablynx, and Upstream Biosciences, and remains as a Director of Barrier Therapeutics.

Yves Ribeill, PhD, serves as Chief Executive Officer of Scynexis, Inc. Prior to founded Scynexis in 2000, Yves held various senior positions in Chemistry during the 20 years of his international career with Rhone-Poulenc then Aventis. Yves served as Director of Entomed (2004-2006) and also serves as Director of Scynexis.

For further lnformation, please contact:
EUROSCREEN S.A.
Tel: +32 71 348 500, Fax: +32 71 348 519
Email: info @ euroscreen.com
Jean Combalbert, Ph.D.
Chief Executive Officer

About EUROSCREEN S.A.
EUROSCREEN is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs. Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, EUROSCREEN is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets.

EUROSCREEN pursues a dual business model strategy of combining its internal programs on high value targets (EUROSCREEN DRUG DISCOVERY) with its fully dedicated Business Unit (EUROSCREEN FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world.

EUROSCREEN has also developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2.

EUROSCREEN has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Monogram Biosciences, Novartis and Pfizer.

###